GlassScriptPhysician profile
Edna Yee
NPI 1205975497
$2,331.77
in general payments reported to CMS, 2019-2025
20 companies · $67.77 in 2025
The $67.77 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $37.16 · 2022: $645 · 2023: $1,139 · 2024: $443 · 2025: $67.77.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,649.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,649.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $560.62 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $181.41 | 2021-2025 | |
| Glaxosmithkline, LLC. | $173.18 | 2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $171.09 | 2022-2024 | Jardiance, Stiolto Respimat, Spiriva Respimat |
| Lilly USA, LLC | $170.00 | 2022-2024 | Mounjaro, Zepbound, Emgality |
| Viiv Healthcare Company | $156.84 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $139.68 | 2022-2024 | Breztri, Airsupra, Farxiga |
| Teva Pharmaceuticals USA, INC. | $117.21 | 2022-2023 | Austedo, Austedo Xr |
| Astellas Pharma US INC | $114.42 | 2022-2024 | Veozah, Myrbetriq |
| Lexicon Pharmaceuticals, INC. | $113.96 | 2024 | Inpefa |
| Scilex Pharmaceuticals INC. | $110.30 | 2022-2023 | Ztlido |
| Pfizer INC. | $78.99 | 2023-2024 | |
| Lundbeck LLC | $57.19 | 2023-2024 | Rexulti |
| Amgen INC. | $46.37 | 2023 | Evenity, Prolia, Repatha |
| Neurocrine Biosciences, INC. | $28.33 | 2023 | Ingrezza |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $27.46 | 2024 | Rexulti |
| Merck Sharp & Dohme LLC | $26.38 | 2023 | M-M-R II, Gardasil 9, Vaxneuvance |
| Janssen Pharmaceuticals, INC | $25.52 | 2023 | Xarelto |
| Arbor Pharmaceuticals, INC. | $20.80 | 2021 | |
| Daiichi Sankyo INC. | $12.02 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edna Yee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.